NGM Bio Announces Oral Plenary Presentation Of Data From Phase 2b ALPINE 4 Trial Of Aldafermin In Compensated Cirrhosis Due To NASH At Upcoming AASLD The Liver Meeting
Portfolio Pulse from Benzinga Newsdesk
NGM Bio has announced that it will present data from its Phase 2b ALPINE 4 trial of Aldafermin in compensated cirrhosis due to NASH at the upcoming AASLD The Liver Meeting. The presentation will be an oral plenary.
October 11, 2023 | 8:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
NGM Bio is set to present data from its Phase 2b ALPINE 4 trial of Aldafermin, which could potentially impact the company's stock depending on the results.
The presentation of the trial data is a significant event for NGM Bio. The results of the trial could potentially have a positive or negative impact on the company's stock, depending on whether the data is perceived positively or negatively by investors. Therefore, the score is neutral until the data is presented and the market reacts.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100